November 17, 2020 Comments Off on NeuroBo Pharmaceuticals (NRBO) & Gemphire Therapeutics Securities Investigation Blog, Current Investigations

NeuroBo Pharmaceuticals (NRBO) & Gemphire Therapeutics Securities Investigation

NeuroBo Pharmaceuticals (NRBO) (Gemphire Therapeutics (Nasdaq: GEMP) Securities Investigation, featured by top securities fraud attorneys, The White Law Group

NeuroBo Pharmaceuticals (NRBO) Merges with Gemphire Therapeutics (Nasdaq: GEMP) on December 31, 2019.

The White Law Group is investigating potential securities claims involving broker-dealers who may have unsuitably recommended Gempshire Therapeutics to investors.

Gemphire Therapeutics filed a form D to raise capital from investors in 2017. The total offering amount sold was purportedly $12,540,704.

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases,completed a merger with Gemphire Therapeutics (Nasdaq: GEMP) on December 31, 2019. Shares of the Combined Company, NeuroBo Pharmaceuticals, began Trading on the Nasdaq Exchange Under the Symbol NRBO on December 31, 2019.

According to Market Watch as of November 15, 2020, shares of NRBO are down more than -30% YTD. 

The problem with pharmaceutical and biotech investments is that they typically involve a high degree of risk. The research and development process for pharma companies often involves costly and lengthy testing trials that yield specific data. If the expected data or end points are not met, that could be bad news for investors.

Broker dealers are required to perform adequate due diligence on any investment they recommend and to ensure that all recommendations are suitable for the investor. Firms that fail to do so, may be held responsible for any losses in a FINRA arbitration claim.

If a broker or brokerage firm makes an unsuitable investment recommendation or fails to adequately disclose the risks associated with an investment they may be found liable for investment losses in a FINRA arbitration claim. Fortunately, FINRA provides an arbitration forum for investors to resolve such disputes.

Filing a Complaint against your Brokerage Firm

If you are concerned about your investment in NeuroBo Pharmaceuticals or Gempshire Therapeutics, you may be able to file a complaint against your brokerage firm. Please contact the securities attorneys at The White Law Group at 1-888-637-5510 for a free consultation. 

The White Law Group is a national securities fraud, securities arbitration, and investor protection law firm with offices in Chicago, Illinois. The firm represents investors throughout the country in claims against their brokerage firm.

For more information on the firm and its representation of investors, visit  www.WhiteSecuritiesLaw.com.

Comments are closed.